Valuation : CSL Limited

Market Cap 5.99TCr 5.14TCr 4.81TCr 4.41TCr 8.3TCr 5,72100Cr 8.33TCr 57TCr 22TCr 2,88300Cr 22TCr 22TCr 9,54300Cr P/E 2027 *
20.6x
P/E 2028 * 18.7x
Enterprise Value 6.9TCr 5.93TCr 5.55TCr 5.08TCr 9.57TCr 6,59300Cr 9.6TCr 66TCr 26TCr 3,32300Cr 26TCr 25TCr 10,99700Cr EV / Sales 2027 *
4.39x
EV / Sales 2028 * 4.22x
Free-Float
99.97%
Yield 2027 *
2.41%
Yield 2028 * 2.55%
1 day-0.90%
1 week+3.51%
Current month+40.03%
1 month+48.05%
3 months+77.83%
6 months+18.01%
Current year-0.19%
1 week 166.28
Extreme 166.28
175.94
1 month 114.26
Extreme 114.26
175.94
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap.
23/02/26 Free

Director

263 0.0001%
23/02/26 Free 512 0.0001%
19/02/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%+3.51%-19.91%-35.69% 5.99TCr
-0.87%-2.29%+37.61%-2.73% 8.07TCr
-4.60%+7.09%+468.80%+27.55% 5.7TCr
+0.76%+3.53%+0.08%+36.18% 5.33TCr
-0.50%-0.41%+10.18%+168.68% 4.93TCr
+0.19%+3.34%+62.44%-16.23% 3.27TCr
-0.30%+0.41%+50.57%+100.03% 2.59TCr
-0.09%+4.98%+18.59%+209.35% 2.39TCr
+0.38%+0.86%+62.15%+124.26% 1.71TCr
-4.68%+2.52%-9.33%+752.25% 1.57TCr
Average -0.65%+2.30%+68.12%+136.37% 4.15TCr
Weighted average by Cap. -0.49%+2.05%+81.30%+73.29%

Financials

2027 *2028 *
Net sales 1.57TCr 1.35TCr 1.26TCr 1.16TCr 2.18TCr 1,50300Cr 2.19TCr 15TCr 5.86TCr 76TCr 5.91TCr 5.78TCr 2,50700Cr 1.63TCr 1.4TCr 1.31TCr 1.2TCr 2.26TCr 1,55400Cr 2.26TCr 15TCr 6.05TCr 78TCr 6.11TCr 5.98TCr 2,59300Cr
Net income 281.8Cr 241.89Cr 226.47Cr 207.37Cr 390.65Cr 27TCr 391.75Cr 2.68TCr 1.05TCr 14TCr 1.06TCr 1.04TCr 45TCr 315.57Cr 270.89Cr 253.61Cr 232.23Cr 437.47Cr 30TCr 438.71Cr 3TCr 1.17TCr 15TCr 1.18TCr 1.16TCr 50TCr
Net Debt 912.85Cr 783.59Cr 733.61Cr 671.76Cr 1.27TCr 87TCr 1.27TCr 8.69TCr 3.4TCr 44TCr 3.43TCr 3.35TCr 1,45400Cr 873.22Cr 749.57Cr 701.76Cr 642.59Cr 1.21TCr 83TCr 1.21TCr 8.31TCr 3.25TCr 42TCr 3.28TCr 3.21TCr 1,39100Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
28/26/28 A$172.32 -0.90% 11,58,131
27/26/27 A$173.88 +0.84% 8,74,276
26/26/26 A$172.44 -0.69% 10,14,011
25/26/25 A$173.64 +2.68% 12,12,519
24/26/24 A$169.11 +0.48% 11,38,160
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
125.08USD
Average target price
117.07USD
Spread / Average Target
-6.40%

Quarterly revenue - Rate of surprise